Engineered immune cells target Virus-Driven cancers in new trial
NCT ID NCT07306156
Summary
This early-phase trial is testing a new cell therapy called GP350 CAR-T for adults with certain lymphomas linked to Epstein-Barr virus (EBV) that have relapsed or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and infuse them back after a short course of chemotherapy. The main goals are to see if the treatment shrinks tumors, clears the virus from the blood, and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV ASSOCIATED LYMPHOID NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.